期刊
DIABETES CARE
卷 33, 期 1, 页码 17-22出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc09-1502
关键词
-
资金
- Medtronic MiniMed
- Animas Corp/Lifescan
- Medtronic and advisory board for Medtronic
- Abbott Diabetes Care and Lifescan
OBJECTIVE - To determine whether continuous glucose monitoring (CGM) is effective in the management of type 1 diabetes when implemented in a manner that more closely approximates clinical practice. RESEARCH DESIGN AND METHODS - After completion of a 6-month randomized controlled trial (RCT) evaluating CGM in children, adolescents, and adults with type I diabetes, CGM was initiated in the trial's control group with less intensive training and follow-up than was included in the RCT. Subjects had an outpatient training session, two follow-up phone calls, and outpatient visits at 1, 4, 13, and 26 weeks. For subjects with baseline AIC >= 7.0%, the primary outcome was change in AIC at 6 months. RESULTS - CGM use decreased from a median of 7.0 days/week in the first month in the >= 25-year-old group, 6.3 days/week in the 15-24 year olds, and 6.8 days/week in the 8-14 year olds to 6.5, 3.3, and 3.7 days/week in the 6th month, respectively (P < 0.001 for each age-group). Among subjects with baseline A1C >= 7.0%, CGM use was associated with A1C reduction after 6 months (P = 0.02 adjusted for age-group). Severe hypoglycemia decreased from 27.7 events per 100 person-years in the 6-month control phase of the RCT to 15.0 events per 100 person-years in the 6-month follow-up CGM phase (P = 0.08). CONCLUSIONS - Frequent use of CGM in a clinical care setting may improve A1C and reduce episodes of hypoglycemia. However, sustained frequent use of CGM is less likely in children and adolescents than in adults.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据